Karen Carey

Biopharma deals and M&As down slightly, but respectable showing despite pandemic

April 7, 2020

With nearly a quarter of the activity announced in March focused on COVID-19, the first quarter of 2020 appears to be on target to beat the deal and M&A values of two of the last three years, although it remains behind 2019. Despite the uncertainty of the coronavirus pandemic, let alone the upcoming U.S. presidential election, the industry has fared relatively well in terms of dealmaking so far this year, even as the markets have plummeted and partnering events have moved to a virtual format. In fact, deals should logically increase as the pandemic takes its toll on the economy, according to a biopharma executive who responded to a recent J.P. Morgan survey.

Med-tech deal and M&A values drop in Q1, significantly down from last year

April 3, 2020

By Karen Carey

No Comments

A flurry of deal and M&A activity in the med-tech industry during the first quarter of 2020 has not translated into high financials, as many of the transactions are not disclosing terms. While the COVID-19 pandemic rages on, business development activities appear to be slumping in recent weeks, leaving the early part of the year significantly down from prior quarters.

Bio-Europe Spring 2020

Closing panel offers COVID-19 lessons to learn from China

March 31, 2020

By Karen Carey

No Comments

Biopharma industry leaders in China who were the first to experience the chaos of the COVID-19 pandemic shared their thoughts during a closing plenary session of the virtual Bio-Europe Spring 2020 meeting.

BioWorld Financings Reports: Cancer, neurology, endocrine take 47% of funding in 2019

March 30, 2020

By Karen Carey

No Comments

A comparison of the last three years puts 2019 on top for having brought the most money into the biopharma industry across 15 key therapeutic markets – a total of $299.78 billion vs. $284.7 billion in 2018 and $201.56 billion in 2017. The analyses includes financings tracked by BioWorld and deals and grants that are within the Cortellis database, all covering therapeutic areas included within the corresponding BioWorld Financings Reports for 2019.

Bio-Europe Spring 2020

Conferences go virtual, postpone, as COVID-19 spreads and Bio-Europe Spring wraps up

March 27, 2020

By Karen Carey

No Comments

The five-day Bio-Europe Spring 2020 conference, possibly the first ever life sciences partnering event staged in an all-virtual format, ended on Friday, March 27, with high hopes that the industry would return to face-to-face interactions next year in Barcelona.

Bio-Europe Spring 2020

Closing panel offers COVID-19 lessons to learn from China

March 27, 2020

By Karen Carey

No Comments

Biopharma industry leaders in China who were the first to experience the chaos of the COVID-19 pandemic shared their thoughts during a closing plenary session of the virtual Bio-Europe Spring 2020 meeting.

Bio-Europe Spring 2020

Partnering plows through a pandemic with the restaged virtual Bio-Europe Spring conference

March 25, 2020

By Karen Carey

No Comments

At the beginning of this week, the digitally-delivered Bio-Europe Spring 2020 conference launched with 6,000 partnering meetings, 45 company presentations, more than 50 virtual exhibits and 12 panel discussions scheduled.

Bio-Europe Spring 2020

Moving in record time, industry, government, investors focus on one mission: Beat COVID-19

March 24, 2020

By Karen Carey

No Comments

Business as usual only three months ago has transformed into health care industry overdrive as biopharma and med-tech companies scramble to test and scale-up treatments, vaccines and diagnostics to address COVID-19.

Bio-Europe Spring 2020

Interrupting disease by plugging into the grid and pulling down innovation

March 24, 2020

By Karen Carey

No Comments

Before becoming the global head of Johnson & Johnson External Innovation, William Hait spent 30 years in academic medicine focused on oncology. Whenever he speaks to a group, the first question he asks is if there is anyone in the room that would like to get a disease.

Drugs on Deck

Ozanimod, Rizaport Versafilm and Triferic awaiting FDA approvals this week

March 23, 2020

By Karen Carey

No Comments

Three candidates for FDA approval remain on BioWorld’s Drugs on Deck list for March, all of which have PDUFA dates scheduled for this month, even though most of the agency’s attention as of late is on the COVID-19 pandemic.

Karen Carey

ARTICLES

Biopharma deals and M&As down slightly, but respectable showing despite pandemic

Med-tech deal and M&A values drop in Q1, significantly down from last year

Closing panel offers COVID-19 lessons to learn from China

BioWorld Financings Reports: Cancer, neurology, endocrine take 47% of funding in 2019

Conferences go virtual, postpone, as COVID-19 spreads and Bio-Europe Spring wraps up

Closing panel offers COVID-19 lessons to learn from China

Partnering plows through a pandemic with the restaged virtual Bio-Europe Spring conference

Moving in record time, industry, government, investors focus on one mission: Beat COVID-19

Interrupting disease by plugging into the grid and pulling down innovation

Ozanimod, Rizaport Versafilm and Triferic awaiting FDA approvals this week

Popular Stories

South Korea approves first four COVID-19 test kits under urgent-use license

Two South Korean COVID-19 kits look overseas, seek FDA approval

Noninvasive ventilation options explored for COVID-19, as FDA eases with guidance

FDA says yes to NO: Bellerophon Therapeutics wins expanded access approval for inhaled nitric oxide system

Antiviral favipiravir effective against COVID-19, China says

BioWorld Premium